



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Tacrolimus Ointment

Page: 1 of 4

Effective Date: 8/30/2024

Last Review Date: 7/2024

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Tacrolimus Ointment under the patient's prescription drug benefit.

Description:

FDA-APPROVED INDICATIONS

Tacrolimus Ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable.

Tacrolimus Ointment is not indicated for children younger than 2 years of age.

Compendial Uses

Psoriasis - on the face, genitals, or skin folds

Vitiligo on the head or neck

Atopic Dermatitis for patients under 2 years of age (tacrolimus ointment 0.03%)

Applicable Drug List:

Preferred: tacrolimus 0.1% topical ointment

Preferred: tacrolimus 0.03% topical ointment

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The request is for tacrolimus 0.03% ointment
OR
- The request is for tacrolimus 0.1% ointment
AND
 - The patient is 16 years of age or older

AND

- The requested drug is being prescribed for psoriasis on the face, genitals, or skin folds



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Tacrolimus Ointment

Page: 2 of 4

Effective Date: 8/30/2024

Last Review Date: 7/2024

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

AND

- The request is NOT for continuation of therapy
- OR
- The request is for continuation of therapy

AND

- The patient has achieved or maintained a positive clinical response as evidenced by improvement (e.g., clear, or almost clear outcome, patient satisfaction, etc.)

OR

- The requested drug is being prescribed for vitiligo on the head or neck

AND

- The request is NOT for continuation of therapy
- OR
- The request is for continuation of therapy

AND

- The patient has achieved or maintained a positive clinical response as evidenced by improvement (e.g., meaningful repigmentation)

OR

- The requested drug is being prescribed for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis (eczema)

AND

- The request is NOT for continuation of therapy
- AND

- The patient is less than 2 years of age

OR

- The requested drug will be used on sensitive skin areas (e.g., face, genitals, or skin folds)

OR



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Tacrolimus Ointment

Page:

3 of 4

Effective Date: 8/30/2024

Last Review Date: 7/2024

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

- The patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one first line therapy agent (e.g., medium or higher potency topical corticosteroid)

OR

- The request is for continuation of therapy

AND

- The patient has achieved or maintained a positive clinical response as evidenced by improvement [(e.g., improvement in or resolution of any of the following signs and symptoms: erythema (redness), edema (swelling), xerosis (dry skin), erosions, excoriations (evidence of scratching), oozing and crusting, lichenification (epidermal thickening), OR pruritus (itching)]

Approval Duration and Quantity Restrictions:

Approval:

Short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis (eczema) in patients 2 years of age and older: Initial: 3 months; Renewal: 36 months

Short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis (eczema) in patients less than 2 years of age: Initial and Renewal: 3 months

Psoriasis on the face, genitals, or skin folds: Initial: 3 months; Renewal: 36 months

Vitiligo on the head or neck: Initial: 3 months; Renewal: 36 months

References:

1. Protopic [package insert]. Madison, NJ: Leo Pharma US, Inc.; February 2019.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed February 21, 2023.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: February/21/2023).
4. Eichenfield L, Tom W, et al. Guidelines of Care for the Management of Atopic Dermatitis. Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. J Am Acad Dermatol. 2014;71:116-32.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Tacrolimus Ointment

Page:

4 of 4

Effective Date: 8/30/2024

Last Review Date: 7/2024

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

5. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol.* 2021 Feb;84(2):432-470.
6. Kubelis-López DE, Zapata-Salazar NA, et al. Updates and new medical treatments for vitiligo (Review). *Exp Ther Med.* 2021;22(2):797.
7. Eleftheriadou V, Atkar R, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. *The British Journal of Dermatology.* 2021;186(1):18-29.
8. Eichenfield LF, Tom WL, et al. Guidelines of Care for the Management of Atopic Dermatitis: Section 1. Diagnosis and Assessment of Atopic Dermatitis. *J Am Acad Dermatol* 2014; 70:338-51.